331 related articles for article (PubMed ID: 32478682)
1. Taxane resistance in prostate cancer is mediated by decreased drug-target engagement.
Gjyrezi A; Xie F; Voznesensky O; Khanna P; Calagua C; Bai Y; Kung J; Wu J; Corey E; Montgomery B; Mace S; Gianolio DA; Bubley GJ; Balk SP; Giannakakou P; Bhatt RS
J Clin Invest; 2020 Jun; 130(6):3287-3298. PubMed ID: 32478682
[TBL] [Abstract][Full Text] [Related]
2. Loss of SLCO1B3 drives taxane resistance in prostate cancer.
de Morrée ES; Böttcher R; van Soest RJ; Aghai A; de Ridder CM; Gibson AA; Mathijssen RH; Burger H; Wiemer EA; Sparreboom A; de Wit R; van Weerden WM
Br J Cancer; 2016 Sep; 115(6):674-81. PubMed ID: 27537383
[TBL] [Abstract][Full Text] [Related]
3. Combination Treatment with Orlistat-Containing Nanoparticles and Taxanes Is Synergistic and Enhances Microtubule Stability in Taxane-Resistant Prostate Cancer Cells.
Souchek JJ; Davis AL; Hill TK; Holmes MB; Qi B; Singh PK; Kridel SJ; Mohs AM
Mol Cancer Ther; 2017 Sep; 16(9):1819-1830. PubMed ID: 28615298
[TBL] [Abstract][Full Text] [Related]
4. Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers.
Wang R; Wang H; Wang Z
J Vis Exp; 2017 Feb; (120):. PubMed ID: 28287508
[TBL] [Abstract][Full Text] [Related]
5. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
Martin SK; Kyprianou N
Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
[TBL] [Abstract][Full Text] [Related]
6. Docetaxel/cabazitaxel and fatty acid binding protein 5 inhibitors produce synergistic inhibition of prostate cancer growth.
Carbonetti G; Converso C; Clement T; Wang C; Trotman LC; Ojima I; Kaczocha M
Prostate; 2020 Jan; 80(1):88-98. PubMed ID: 31661167
[TBL] [Abstract][Full Text] [Related]
7. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer.
Darshan MS; Loftus MS; Thadani-Mulero M; Levy BP; Escuin D; Zhou XK; Gjyrezi A; Chanel-Vos C; Shen R; Tagawa ST; Bander NH; Nanus DM; Giannakakou P
Cancer Res; 2011 Sep; 71(18):6019-29. PubMed ID: 21799031
[TBL] [Abstract][Full Text] [Related]
8. Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors.
Vrignaud P; Sémiond D; Lejeune P; Bouchard H; Calvet L; Combeau C; Riou JF; Commerçon A; Lavelle F; Bissery MC
Clin Cancer Res; 2013 Jun; 19(11):2973-83. PubMed ID: 23589177
[TBL] [Abstract][Full Text] [Related]
9. βIII-tubulin enhances efficacy of cabazitaxel as compared with docetaxel.
Smiyun G; Azarenko O; Miller H; Rifkind A; LaPointe NE; Wilson L; Jordan MA
Cancer Chemother Pharmacol; 2017 Jul; 80(1):151-164. PubMed ID: 28567478
[TBL] [Abstract][Full Text] [Related]
10. Microtubule Engagement with Taxane Is Altered in Taxane-Resistant Gastric Cancer.
Galletti G; Zhang C; Gjyrezi A; Cleveland K; Zhang J; Powell S; Thakkar PV; Betel D; Shah MA; Giannakakou P
Clin Cancer Res; 2020 Jul; 26(14):3771-3783. PubMed ID: 32321717
[TBL] [Abstract][Full Text] [Related]
11. Exploiting epigenetic targets to overcome taxane resistance in prostate cancer.
Cevatemre B; Bulut I; Dedeoglu B; Isiklar A; Syed H; Bayram OY; Bagci-Onder T; Acilan C
Cell Death Dis; 2024 Feb; 15(2):132. PubMed ID: 38346967
[TBL] [Abstract][Full Text] [Related]
12. Regulation of eIF4F Translation Initiation Complex by the Peptidyl Prolyl Isomerase FKBP7 in Taxane-resistant Prostate Cancer.
Garrido MF; Martin NJ; Bertrand M; Gaudin C; Commo F; El Kalaany N; Al Nakouzi N; Fazli L; Del Nery E; Camonis J; Perez F; Lerondel S; Le Pape A; Compagno D; Gleave M; Loriot Y; Désaubry L; Vagner S; Fizazi K; Chauchereau A
Clin Cancer Res; 2019 Jan; 25(2):710-723. PubMed ID: 30322877
[TBL] [Abstract][Full Text] [Related]
13. Sensitivity of docetaxel-resistant MCF-7 breast cancer cells to microtubule-destabilizing agents including vinca alkaloids and colchicine-site binding agents.
Wang RC; Chen X; Parissenti AM; Joy AA; Tuszynski J; Brindley DN; Wang Z
PLoS One; 2017; 12(8):e0182400. PubMed ID: 28787019
[TBL] [Abstract][Full Text] [Related]
14. DNA-PKc inhibition overcomes taxane resistance by promoting taxane-induced DNA damage in prostate cancer cells.
Chao OS; Goodman OB
Prostate; 2021 Oct; 81(14):1032-1048. PubMed ID: 34297853
[TBL] [Abstract][Full Text] [Related]
15. ABCB1 Mediates Cabazitaxel-Docetaxel Cross-Resistance in Advanced Prostate Cancer.
Lombard AP; Liu C; Armstrong CM; Cucchiara V; Gu X; Lou W; Evans CP; Gao AC
Mol Cancer Ther; 2017 Oct; 16(10):2257-2266. PubMed ID: 28698198
[TBL] [Abstract][Full Text] [Related]
16. Taxane refractory prostate cancer.
Mathew P; Dipaola R
J Urol; 2007 Sep; 178(3 Pt 2):S36-41. PubMed ID: 17644120
[TBL] [Abstract][Full Text] [Related]
17. Intra versus Inter Cross-resistance Determines Treatment Sequence between Taxane and AR-Targeting Therapies in Advanced Prostate Cancer.
Lombard AP; Liu L; Cucchiara V; Liu C; Armstrong CM; Zhao R; Yang JC; Lou W; Evans CP; Gao AC
Mol Cancer Ther; 2018 Oct; 17(10):2197-2205. PubMed ID: 29891490
[TBL] [Abstract][Full Text] [Related]
18. The Wnt non-canonical signaling modulates cabazitaxel sensitivity in prostate cancer cells.
Sennoune SR; Nelius T; Jarvis C; Pruitt K; Kottapalli KR; Filleur S
PLoS One; 2020; 15(6):e0234078. PubMed ID: 32484838
[TBL] [Abstract][Full Text] [Related]
19. Molecular complexity of taxane-induced cytotoxicity in prostate cancer cells.
Mang J; Merkle K; Heller M; Schüler J; Tolstov Y; Li J; Hohenfellner M; Duensing S
Urol Oncol; 2017 Jan; 35(1):32.e9-32.e16. PubMed ID: 27692847
[TBL] [Abstract][Full Text] [Related]
20. Preclinical profile of cabazitaxel.
Vrignaud P; Semiond D; Benning V; Beys E; Bouchard H; Gupta S
Drug Des Devel Ther; 2014; 8():1851-67. PubMed ID: 25378905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
